anyone? b/c they have 126 million outstanding shares. I am worry that they will do reverse split, then we will be like CLSN and ZLCS down more than 20% on the first day of R/S
We need to get the news on the trials first and get the stock up to $1. Then a 1:5 reverse split and uplisting make sense. Doing it now would not, as the reverse would have to be 1:15, and the stock would be too illiquid.
I'd rather follow CPRX trajectory from earlier this year (not recent) going from .40 to .60, then coverage initiated with strong buy driving stock over $1. Achievement of milestones and progress in studies bringing price up over $4 in 6months.
This is just bashing. You don't need a reverse split when this is the near-term potential. The following are estimates that can be found in analysts estimates of the Melanoma and merkel cell market, to include orphan status at minimum:
BrotherBear--"Bio-techs with products on the market generally trade with a pps 3-5 times their annual sales divided by outstanding shares. Example: Company XYZ has annual sales of $400MM, with 200MM outstanding shares, could expect to trade between $5-$10 pps. Now, if a company has orphan designation for their product the multiple can increase quite substantially.
Right now, many analysts have projected sale for ONCS at $500MM possible for Melanoma and $100MM possible for MCC. That would be $600MM possible annual sales (to start), with let's call it 200MM outstanding shares (thus including the warrants currently being executed), AND one must consider that ONCS has a distinct possibility of receiving orphan designation from the FDA.
I'll leave the math on this one up to you, but the potential is extremely high here. You would be hard pressed to find another company with so much potential."
This isn't a "Dare to Believe" speech...it's based on biotech data patterns and real stock valuations. Don't let the ignorant ramblings of newbies or manipulative questioning of the Bashers dull your intelligence down to the level of a pawn to be pushed around on this board. Get your head clear about why your invested here and stand on the best-in-class data that we already have!
Sentiment: Strong Buy
There is nothing wrong when a good company does a r/s for the right reasons. I would vote for one for the simple fact we become a more attractive company to institutions. I own 250'000 shares.
I agree. A reverse split from ONCS would be done to get uplisted and not save themselves from delisting. I know it is pure speculation at this time but I do not think there is a single fundamental reason that a reverse split would be bad for the company. It would definitely cut the volatility down from the day traders manipulating the price daily.
Sentiment: Strong Buy
this is so not true. anytime a biotech does an RS it almost always leads to a nose dive. look at zlcs. an rs would be bad for shareholders, great for future investors. this happens 99% of the time. oncs hopefully goes up organically.
not in the near future, but an RS would be good for the company because it would attract larger institutions. zlcs did an RS to stay on the nasdaq, oncs doesnt have that problem because it isnt listed yet. regardless, oncs cannot do another offering. if it does another then we KNOW an RS will have to happen at some point.
this is a valid question, regardless of this commentors motivation. saw the same thing at zlcs, anyone who spoke ill of the RS was deemed a basher. guess what, zlcs lost what - 30% of its value in like a week? LOL.
Tiger, watch out for Bull. He's kind of nuts. Has he threatened you with cancer yet? I mentioned the very same fact thing in a previous post and I could see pieces of Bulls head splattered all over his return to my post.
Companies all have their reasons for RS. The nice thing is that they are transparent and everybody can see what their motivation. It's either out of fear or certainty. Me personally, a RS in ONCS should things go well in Phase II would be an incredibly smart move and attractive to the type of investor that everybody hopes will hop on board.
This is just another bashing tactic...they act like they are for the stock and want info but are just trying to put a bug in possible investors ears. He wasn't asking a question...just being a douche
Good catch on the soft bash grleroy, notice it didn't mention that Dhillion has already stated he want's the $1 mark to be reached organically. And of coarse not to mention OncoSec is already funded and already has powerful milestones within the next 60 days.
Sentiment: Strong Buy